Fig. 5 -.
Analisi di scenario: curva di accettabilità del rapporto costo-efficacia incrementale di caplacizumab in associazione con PEX e immunosoppressione rispetto a PEX e immunosoppressione.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.